LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

Search

ESPERION THERAPEUTICS INC

Chiusa

SettoreSettore sanitario

0.85 -5.56

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.83

Massimo

0.91

Metriche Chiave

By Trading Economics

Entrata

-19M

-40M

Vendite

-4.1M

65M

EPS

-0.206

Margine di Profitto

-62.243

Dipendenti

304

EBITDA

-17M

-22M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+593.41% upside

Dividendi

By Dow Jones

Utili prossimi

11 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

13M

171M

Apertura precedente

6.41

Chiusura precedente

0.85

Notizie sul Sentiment di mercato

By Acuity

50%

50%

187 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

ESPERION THERAPEUTICS INC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2025, 23:25 UTC

Azioni calde

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mag 2025, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mag 2025, 21:29 UTC

Acquisizioni, Fusioni, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 mag 2025, 21:01 UTC

I principali Market Mover

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mag 2025, 23:49 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mag 2025, 23:37 UTC

Discorsi di Mercato

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mag 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mag 2025, 23:32 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mag 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mag 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mag 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mag 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mag 2025, 23:28 UTC

Utili

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mag 2025, 23:27 UTC

Utili

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mag 2025, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mag 2025, 23:22 UTC

Notizie principali

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 mag 2025, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mag 2025, 23:20 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mag 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mag 2025, 23:04 UTC

Notizie principali

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 mag 2025, 21:46 UTC

Notizie principali

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 mag 2025, 21:42 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mag 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 mag 2025, 21:07 UTC

Notizie principali

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mag 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Confronto tra pari

Modifica del prezzo

ESPERION THERAPEUTICS INC Previsione

Obiettivo di Prezzo

By TipRanks

593.41% in crescita

Previsioni per 12 mesi

Media 6.31 USD  593.41%

Alto 16 USD

Basso 1.85 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ESPERION THERAPEUTICS INC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

4

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.85 / 1.05Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

187 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.